Print
Parent Category: Neurolixis
Category: Presentation
Also available:  French (fr-FR) 
Hits: 36947

 

Adrian Newman-Tancredi, PhD, DSc, Co-founder, President and CEO

Dr. Newman-Tancredi has broad expertise in neuroscience drug discovery and early pre-clinical development. He was previously Director of Neurobiology and Project Manager at Pierre Fabre Laboratories. More...

 

Steven A. Johnson, PhD, Vice-President, Drug Development

Dr. Johnson has extensive experience of pre-clinical and clinical drug development in neurobiology and neuropsychiatry. He was previously Vice-President and Executive Officer at Cortex Pharmaceuticals. More...

 

Ronan Depoortere, PhD, Director, Pharmacology

Dr. Depoortere is a highly experienced pharmacologist and participated in the characterization of antipsychotics and antidepressants. He was previously Senior Scientist at Sanofi and Synthelabo. More...

 

Mark S. Kleven, PhD, Chief Operations Officer 

Dr. Kleven has wide experience in small and mid-sized pharma companies as a pharmacologist and manager of FDA, NIH and DOD-compliant dossiers. He was previously VP at Biousian Systems and Ceptaris. More...

 

Mark A. Varney, PhD, Co-founder, Director

Dr. Varney has spent over two decades in pharmaceutical research and was previously Chief Executive Officer of Cortex Pharmaceuticals, and Vice-President and Head of Discovery at Sepracor (now Sunovion). More...

 

Fabienne Herbrecht, PhD, Director, Clinical Development

Dr Herbrecht has over 25 years of experience in the Human and Veterinary Pharmaceutical Industry, working in three main areas: clinical development, quality assurance and regulatory affairs. More...

 

Violette Richin, DPharm, Researcher in Radioimaging 

Violette Richin is Doctor of Pharmacy and graduated from the University of Lyon. She completed her training with a Master degree in Medicinal Chemistry and Molecular Pharmacology at the University of Paris.  More...